




Instance: composition-en-4c889264e6df1e0383b0ef68358c4009
InstanceOf: CompositionUvEpi
Title: "Composition for sivextro Package Leaflet"
Description:  "Composition for sivextro Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/15/991/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp4c889264e6df1e0383b0ef68358c4009)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - sivextro"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Sivextro is and what it is used for</li>
<li>What you need to know before you take Sivextro</li>
<li>How to take Sivextro</li>
<li>Possible side effects</li>
<li>How to store Sivextro</li>
<li>Contents of the pack and other information</li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What sivextro is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What sivextro is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Sivextro is an antibiotic that contains the active substance tedizolid phosphate. It belongs to a group of
medicines called  oxazolidinones .
It is used to treat adults and adolescents 12 years of age and older with infections of the skin and
tissues below the skin.
It works by stopping the growth of certain bacteria which can cause serious infections.</p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take sivextro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take sivextro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Sivextro 
* if you are allergic to tedizolid phosphate or any of the other ingredients of this medicine (listed
in section 6). 
Warnings and precautions
Your doctor will have decided if Sivextro is suitable to treat your infection.
Talk to your doctor or nurse before taking Sivextro if any of the following apply to you:</p>
<ul>
<li>are suffering from diarrhoea, or have suffered from diarrhoea whilst (or up to 2 months after)
taking antibiotics in the past.</li>
<li>are allergic to other medicines belonging to the group  oxazolidinones  (e.g., linezolid,
cycloserine).</li>
<li>have a history of bleeding or easy bruising (which may be a sign of low numbers of platelets,
the small cells involved in clotting in your blood).</li>
<li>have kidney problems.</li>
<li>are taking certain medicines to treat depression, known as tricyclics, SSRIs (selective serotonin
reuptake inhibitors) or MAOIs (monoamine oxidase inhibitors). See Other medicines and
Sivextro for examples.</li>
<li>are taking certain medicines to treat migraine known as  triptans . See Other medicines and
Sivextro for examples.
Ask your doctor or pharmacist if you are not sure whether you are taking any of these medicines.
Diarrhoea
Contact your doctor straight away if you suffer from diarrhoea during or after your treatment. Do not
take any medicine to treat your diarrhoea without first checking with your doctor.
Resistance to antibiotics
Bacteria can become resistant to treatment with antibiotics over time. This is when antibiotics cannot
stop the growth of bacteria and treat your infection. Your doctor will decide if you should be given
Sivextro to treat your infection. 
Possible side effects
Certain side effects have been observed with Sivextro or another member of the oxazolidinone class
when administered over a duration exceeding that recommended for Sivextro. Tell your doctor straight
away if you suffer from any of the following while taking Sivextro:</li>
<li>a low white blood cell count </li>
<li>anaemia (low red blood cells) </li>
<li>bleeding or bruising easily</li>
<li>loss of sensitivity in your hands or feet (such as numbness, prickling/tingling, or sharp pains)</li>
<li>any problems with your eyesight such as blurred vision, changes in colour vision, difficulty in
seeing detail or if your field of vision becomes restricted.
Children
This medicine should not be used in children under 12 years of age as it has not been studied enough
in this population.
Other medicines and Sivextro
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other
medicines. It is especially important that you tell your doctor if you are also taking:</li>
<li>amitriptyline, citalopram, clomipramine, dosulepin, doxepin, fluoxetine, fluvoxamine,
imipramine, isocarboxazid, lofepramine, moclobemide, paroxetine, phenelzine, selegiline and
sertraline (used to treat depression)</li>
<li>sumatriptan, zolmitriptan (used to treat migraine)</li>
<li>imatinib, lapatinib (used to treat cancer)</li>
<li>methotrexate (used to treat cancer, rheumatoid arthritis or psoriasis)</li>
<li>sulfasalazine (used to treat inflammatory bowel diseases)</li>
<li>topotecan (used to treat cancer)</li>
<li>statins such as pitavastatin, rosuvastatin (used to lower blood cholesterol)
Sivextro can interfere with the effects of these medicines. Your doctor will explain more.
Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask
your doctor or pharmacist for advice before taking this medicine.
It is not known if Sivextro passes into breast milk in humans. Ask your doctor for advice before
breast-feeding your baby.
Driving and using machines
Do not drive or use machines if you feel dizzy or tired after taking this medicine. </li>
</ul> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take sivextro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take sivextro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor
or pharmacist if you are not sure.
The recommended dose is one 200 mg tablet once a day for 6 days. The tablets are swallowed whole
and can be taken with or without food or drink.<br />
Talk to a doctor if you do not feel better, or if you feel worse after 6 days.
If you take more Sivextro than you should
Contact your doctor, pharmacist or nearest hospital casualty department as soon as possible if you
have taken more tablets than you should, and take your medicine with you.
If you forget to take Sivextro
If you forget to take your medicine, take the dose as soon as possible anytime up to 8 hours prior to the
next scheduled dose. If less than 8 hours remains before the next dose, then wait until the next
scheduled dose. Do not take a double dose to make up for a forgotten dose. If in any doubt, contact
your pharmacist for advice.
You should take all 6 tablets to complete your course of treatment, even if you have missed a dose.
If you stop taking Sivextro
If you stop taking Sivextro without the advice of your doctor, your symptoms may get worse. Talk to
your doctor or pharmacist before you stop taking your medicine.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.
Contact your doctor straight away if you suffer from diarrhoea during or after your treatment.
Other side effects may include:
Common side effects (may affect up to 1 in 10 people)
* Nausea
* Vomiting
* Headache
* Itching all over the body
* Tiredness
* Dizziness
Uncommon side effects (may affect up to 1 in 100 people)
* Fungal infections of skin, mouth and vagina (oral / vaginal thrush)
* Itching (including itching due to allergic reaction), hair loss, acne, red and/or itchy rash or hives,
excessive sweating 
* Decrease or loss of skin sensitivity, tingling/prickling skin sensation 
* Hot flush or blushing/redness in the face, neck or upper chest 
* Abscess (swollen, pus-filled lump) 
* Vaginal infection, inflammation or itching 
* Anxiety, irritability, shaking or trembling 
* Respiratory tract (sinuses, throat and chest) infection
* Dryness in the nose, congestion in the chest, cough 
* Sleepiness, abnormal sleep pattern, difficulty sleeping, nightmares (unpleasant/disturbing
dreams)
* Dry mouth, constipation, indigestion, pain/discomfort in the belly (abdomen), retching, dry
heaving, bright red blood in the stool
* Acid reflux disease (heartburn, pain or difficulty swallowing), flatulence/passing wind 
* Joint pain, muscle spasms, back pain, neck pain, pain/discomfort in limbs, decrease of grip
strength
* Blurred vision,  floaters  (small shapes seen floating in the field of vision)
* Swollen or enlarged lymph nodes 
* Allergic reaction 
* Dehydration 
* Poor control of diabetes 
* Abnormal sense of taste 
* Slow heartbeat
* Fever 
* Swelling in ankles and/or feet 
* Abnormal smelling urine, abnormal blood tests 
Frequency not known (frequency cannot be estimated from the available data)
* Bleeding or bruising easily (due to low numbers of platelets, the small cells involved in clotting
in your blood)
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects
not listed in this leaflet. You can also report side effects directly via the national reporting system
listed in Appendix V. By reporting side effects you can help provide more information on the safety of
this medicine.</p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store sivextro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store sivextro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton or blister label after
 EXP . The expiry date refers to the last day of that month.
This medicinal product does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to
throw away medicines you no longer use. These measures will help protect the environment.</p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Sivextro contains
* The active substance is tedizolid phosphate. Each film-coated tablet contains 200 mg of
tedizolid phosphate.
* The other ingredients are microcrystalline cellulose, mannitol, povidone, crospovidone and
magnesium stearate within the tablet core. The film coat of the tablet contains polyvinyl
alcohol, titanium dioxide (E171), macrogol, talc and yellow iron oxide (E172).
What Sivextro looks like and contents of the pack
Sivextro is an oval, yellow film-coated tablet imprinted with  TZD  on one side and  200  on the other
side.
It is available in 6   1 tablets in perforated unit-dose blisters.
Marketing Authorisation Holder and Manufacturer
Merck Sharp &amp; Dohme B.V.
Waarderweg 2031 BN Haarlem
The Netherlands
For any information about this medicine, please contact the local representative of the Marketing
Authorisation Holder:
Belgi /Belgique/Belgien
MSD Belgium
T l/Tel: +32(0)27766dpoc_belux@merck.com
Lietuva
UAB Merck Sharp &amp; Dohme
Tel.: +370 5 278 02 msd_lietuva@merck.com</p>
<p>.: +359 2 819 3info-msdbg@merck.com
Luxembourg/Luxemburg
MSD Belgium
T l/Tel: +32(0)27766dpoc_belux@merck.com
 esk  republika
Merck Sharp &amp; Dohme s.r.o.
Tel.: +420 233 010 dpoc_czechslovak@merck.com
Magyarorsz g
MSD Pharma Hungary Kft.
Tel.: +36 1 888 5hungary_msd@merck.com
Danmark
MSD Danmark ApS
Tlf: +45 4482 4dkmail@merck.com
Malta
Merck Sharp &amp; Dohme Cyprus Limited
Tel: 8007 4433 (+356 99917558)
malta_info@merck.com
Deutschland
MSD Sharp &amp; Dohme GmbH
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)
e-mail@msd.de
Nederland
Merck Sharp &amp; Dohme B.V.
Tel: 0800 9999000 (+31 23 5153153)
medicalinfo.nl@merck.com
Eesti
Merck Sharp &amp; Dohme O 
Tel.: +372 6144 msdeesti@merck.com
Norge
MSD (Norge) AS
Tlf: +47 32 20 73 msdnorge@msd.no</p>
<p>MSD  . . . . .
 : +30 210 98 97 dpoc_greece@merck.com
 sterreich
Merck Sharp &amp; Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 dpoc_austria@merck.com
Espa a
Merck Sharp &amp; Dohme de Espa a, S.A.
Tel: +34 91 321 06 msd_info@merck.com
Polska
MSD Polska Sp. z o.o.
Tel.: +48 22 549 51 msdpolska@merck.com
France
MSD France
T l: + 33 (0) 1 80 46 40 Portugal
Merck Sharp &amp; Dohme, Lda
Tel: +351 21 4465inform_pt@merck.com
Hrvatska
Merck Sharp &amp; Dohme d.o.o.
Tel: + 385 1 6611 croatia_info@merck.com
Rom nia
Merck Sharp &amp; Dohme Romania S.R.L.
Tel: +40 21 529 29 msdromania@merck.com
Ireland
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998medinfo_ireland@merck.com
Slovenija
Merck Sharp &amp; Dohme, inovativna zdravila d.o.o.
Tel: +386 1 5204 msd.slovenia@merck.com
 sland
Vistor hf.
S mi: + 354 535 7Slovensk  republika
Merck Sharp &amp; Dohme, s. r. o.
Tel.: +421 2 58282dpoc_czechslovak@merck.com
 talia
MSD Italia S.r.l.
Tel: 800 23 99 89 (+39 06 361911)
medicalinformation.it@msd.com
Suomi/Finland
MSD Finland Oy
Puh/Tel: +358 (0)9 804 info@msd.fi</p>
<p>Merck Sharp &amp; Dohme Cyprus Limited
 .: 800 00 673 (+357 22866700)
cyprus_info@merck.com
Sverige
Merck Sharp &amp; Dohme (Sweden) AB
Tel: +46 77 5700medicinskinfo@merck.com
Latvija
SIA Merck Sharp &amp; Dohme Latvija
Tel: +371 67364msd_lv@merck.com
United Kingdom (Northern Ireland)
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998medinfoNI@msd.com
This leaflet was last revised in {MM/YYYY}.
Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu.
Package leaflet: Information for the patient
Sivextro 200 mg powder for concentrate for solution for infusion
tedizolid phosphate
Read all of this leaflet carefully before you start receiving this medicine because it contains
important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or nurse.
- If you get any side effects, talk to your doctor or nurse. This includes any possible side effects
not listed in this leaflet. See section 4.</p> </div>"""      



Instance: composition-da-4c889264e6df1e0383b0ef68358c4009
InstanceOf: CompositionUvEpi
Title: "Composition for sivextro Package Leaflet"
Description:  "Composition for sivextro Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/15/991/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp4c889264e6df1e0383b0ef68358c4009)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - sivextro"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. INDLÆGSSEDDEL"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. INDLÆGSSEDDEL"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Indlægsseddel: Information til brugeren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Indlægsseddel: Information til brugeren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "Oversigt over indlægssedlen"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Oversigt over indlægssedlen"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen
1. Virkning og anvendelse
2. Det skal du vide, før du begynder at tage Sivextro
3. Sådan skal du tage Sivextro
4. Bivirkninger
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p> </div>"""   
          

* section[=].section[+]
  * title =  "1. Virkning og anvendelse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. Virkning og anvendelse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Sivextro er et antibiotikum, der indeholder det aktive stof tedizolidphosphat. Det tilhører en gruppe
lægemidler, der kaldes "oxazolidinoner".
Det anvendes til at behandle infektioner i hud og hudstrukturer hos voksne og unge i alderen 12 år og
derover.
Det virker ved at standse væksten af bestemte bakterier, der kan give alvorlige infektioner. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. Det skal du vide, før du begynder at tage  sivextro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. Det skal du vide, før du begynder at tage  sivextro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Sivextro</p>
<ul>
<li>
<p>hvis du er allergisk over for tedizolidphosphat eller et af de øvrige indholdsstoffer i Sivextro
(angivet i punkt 6). 
Advarsler og forsigtighedsregler
Din læge vil tage stilling til, om Sivextro er egnet til at behandle din infektion.
Kontakt lægen eller sygeplejersken, før du tager Sivextro, hvis noget af nedenstående gælder for dig:</p>
</li>
<li>
<p>hvis du har diarré, eller hvis du tidligere har fået diarré, når du har taget antibiotika (eller op til
2 måneder efter, at du har fået antibiotika). </p>
</li>
<li>hvis du er allergisk over for andre lægemidler, der tilhører oxazolidinon-gruppen (f.eks.
linezolid eller cycloserin).</li>
<li>hvis du tidligere har haft tilbøjelighed til at bløde eller få blå mærker (hvilket kan være et tegn
på et lavt antal blodplader, de små celler, der har betydning for blodets evne til at størkne).</li>
<li>hvis du har nyreproblemer.</li>
<li>hvis du tager lægemidler til behandling af depression af typen tricykliske antidepressiva, SSRI
(selektive serotonin-genoptagelseshæmmere), opioider eller MAO-hæmmere
(monoaminooxidasehæmmere). Anvendelse af disse lægemidler sammen med tedizolidphosphat
kan medføre serotoninsyndrom, en potentielt livstruende tilstand (med symptomer som
40
forvirring, koncentrationsbesvær, høj feber, reflekser, der er kraftigere end normalt
(hyperrefleksi), tab af muskelkoordination). Se Brug af andre lægemidler sammen med Sivextro
for eksempler.</li>
<li>
<p>hvis du tager lægemidler til behandling af migræne af typen "triptaner". Se Brug af andre
lægemidler sammen med Sivextro for eksempler.
Spørg din læge eller apotekspersonalet, hvis du ikke er sikker på, om du tager denne type lægemiddel.
Diarré
Kontakt lægen med det samme, hvis du får diarré under eller efter behandlingen. Du må ikke tage
medicin mod diarré, før du har talt med lægen.
Resistens over for antibiotika
Bakterier kan med tiden blive resistente over for antibiotika. Det vil sige, at antibiotika ikke kan
standse bakteriernes vækst og behandle infektionen. Din læge vurderer, om du skal have Sivextro til
behandling af din infektion. 
Mulige bivirkninger
Der er set en række bivirkninger ved brug af Sivextro eller et andet lægemiddel i oxazolidinon-klassen
over en længere periode end den, der anbefales for Sivextro. Fortæl det straks til lægen, hvis en eller
flere af nedenstående tilstande gælder for dig, mens du tager Sivextro:</p>
</li>
<li>
<p>lavt antal hvide blodlegemer</p>
</li>
<li>
<p>blodmangel (lavt antal røde blodlegemer; også kaldet anæmi)</p>
</li>
<li>
<p>tilbøjelighed til at bløde eller få blå mærker</p>
</li>
<li>
<p>manglende følsomhed i hænder og/eller fødder (f.eks. følelsesløshed, prikkende/snurrende
fornemmelse eller stikkende smerter)</p>
</li>
<li>
<p>problemer med øjnene, f.eks. sløret syn, ændret farveopfattelse, udviskede detaljer eller nedsat
synsfelt.
Børn
Dette lægemiddel må ikke bruges til børn under 12 år, da det ikke er undersøgt tilstrækkeligt hos
denne population.
Brug af andre lægemidler sammen med Sivextro
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager andre lægemidler, for nylig har taget
andre lægemidler eller planlægger at tage andre lægemidler. Det er især vigtigt, at du siger det til
lægen, hvis du også tager:</p>
</li>
<li>
<p>amitriptylin, citalopram, clomipramin, dosulepin, doxepin, fluoxetin, fluvoxamin, imipramin,
isocarboxazid, lofepramin, moclobemid, paroxetin, phenelzin, selegilin, sertralin, duloxetin og
venlafaxin (til behandling af depression). Der er en risiko for at tedizolidphosphat kan påvirke
virkningen af visse lægemidler, inklusive de lægemidler, der er nævnt her, og forårsage
bivirkninger såsom ændringer i blodtrykket eller temperatur.</p>
</li>
<li>
<p>sumatriptan, zolmitriptan (til behandling af migræne)</p>
</li>
<li>
<p>opioider (såsom fentanyl)</p>
</li>
<li>
<p>imatinib, lapatinib (til behandling af kræft)</p>
</li>
<li>
<p>methotrexat (til behandling af kræft, leddegigt eller psoriasis)</p>
</li>
<li>
<p>sulfasalazin (til behandling af inflammatoriske (betændelsesagtige) tarmsygdomme)</p>
</li>
<li>
<p>topotecan (til behandling af kræft)</p>
</li>
<li>
<p>statiner som f.eks. pitavastatin, rosuvastatin (mod forhøjet kolesterol)
Sivextro kan have indvirkning på disse lægemidlers effekt. Din læge vil fortælle dig mere om det.
Graviditet og amning
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal
du spørge lægen eller apotekspersonalet til råds, før du tager dette lægemiddel.
41
Det er ukendt, om Sivextro udskilles i mælken hos mennesker. Spørg din læge til råds, før du ammer
dit barn.
Trafik- og arbejdssikkerhed
Du må ikke køre bil eller betjene maskiner, hvis du føler dig svimmel eller træt efter at have taget
dette lægemiddel. </p>
</li>
</ul> </div>"""   
                    
* section[=].section[+]
  * title =  "3. Sådan skal du tage sivextro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. Sådan skal du tage sivextro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller
apotekspersonalet.
Den anbefalede dosis er en 200 mg tablet en gang dagligt i 6 dage. Tabletterne synkes hele og kan
tages med eller uden mad og drikke. 
Kontakt lægen, hvis du ikke får det bedre, eller hvis du får det værre efter 6 dage.
Hvis du har taget for meget Sivextro
Kontakt lægen, apotekspersonalet eller den nærmeste skadestue så hurtigt som muligt, hvis du har
taget for mange tabletter, og medbring medicinen.
Hvis du har glemt at tage Sivextro
Hvis du har glemt at tage din dosis, skal du tage den manglende dosis så hurtigt som muligt, hvis der
er mere end 8 timer til den næste planlagte dosis. Hvis der er under 8 timer til den næste planlagte
dosis, skal du vente til den næste dosis. Du må ikke tage en dobbeltdosis som erstatning for den glemte
dosis. Spørg apotekspersonalet, hvis der er noget, du er tvivl om.
Du skal tage alle 6 tabletter for at gennemføre hele behandlingsforløbet, også hvis du har glemt en
dosis.
Hvis du holder op med at tage Sivextro
Hvis du holder op med at tage Sivextro uden at rådføre dig med lægen, kan dine symptomer blive
værre. Kontakt lægen eller apotekspersonalet, før du holder op med at tage dette lægemiddel.
Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om.</p> </div>"""         

        
* section[=].section[+]
  * title = "4. Bivirkninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Bivirkninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger.
Kontakt lægen med det samme, hvis du får diarré under eller efter behandlingen.
Andre bivirkninger:
Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 patienter)</p>
<ul>
<li>
<p>Kvalme</p>
</li>
<li>
<p>Opkastning</p>
</li>
<li>
<p>Hovedpine</p>
</li>
<li>
<p>Kløe over hele kroppen</p>
</li>
<li>
<p>Træthed</p>
</li>
<li>
<p>Svimmelhed.
Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 patienter)</p>
</li>
<li>
<p>Svampeinfektion i huden, munden og/eller skeden</p>
</li>
<li>
<p>Kløe (herunder kløe, der skyldes en overfølsomhedsreaktion), hårtab, bumser (akne), rødt
og/eller kløende udslæt eller nældefeber, øget svedtendens </p>
</li>
<li>
<p>Nedsættelse eller tab af følsomheden i huden, stikkende/prikkende fornemmelse i huden 
42</p>
</li>
<li>
<p>Hedeture eller rødme i ansigtet eller på halsen og den øvre del af brystkassen </p>
</li>
<li>
<p>Byld (hævet, pusfyldt bule) </p>
</li>
<li>
<p>Infektion, irritation eller kløe i skeden </p>
</li>
<li>
<p>Angst, irritabilitet, rysten eller skælven </p>
</li>
<li>
<p>Luftvejsinfektion (bihuler, hals og brystkasse)</p>
</li>
<li>
<p>Næsetørhed, slim i lungerne, hoste </p>
</li>
<li>
<p>Søvnighed, unormalt søvnmønster, søvnbesvær, mareridt (ubehagelige/forstyrrende drømme)</p>
</li>
<li>
<p>Mundtørhed, forstoppelse, fordøjelsesbesvær, smerter/ubehag i maven,
opkastningsfornemmelse, frisk rødt blod i afføringen</p>
</li>
<li>
<p>Mavesyre-refluks (halsbrand, smerter ved synkning eller synkebesvær), luft i tarmene </p>
</li>
<li>
<p>Ledsmerter, muskelspasmer, rygsmerter, nakkesmerter, smerter/ubehag i lemmerne, nedsat
gribestyrke</p>
</li>
<li>
<p>Sløret syn, "flyvende fluer" (små partikler i synsfeltet)</p>
</li>
<li>
<p>Hævede eller forstørrede lymfeknuder </p>
</li>
<li>
<p>Overfølsomhedsreaktion </p>
</li>
<li>
<p>Dehydrering (væsketab) </p>
</li>
<li>
<p>Dårlig regulering af sukkersyge (diabetes)</p>
</li>
<li>
<p>Smagsforstyrrelser </p>
</li>
<li>
<p>Langsom hjerterytme (puls)</p>
</li>
<li>
<p>Feber </p>
</li>
<li>
<p>Hævede ankler og/eller fødder </p>
</li>
<li>
<p>Unormal urinlugt, unormale blodprøver. 
Hyppighed "Ikke kendt" (hyppigheden kan ikke vurderes ud fra tilgængelige data)</p>
</li>
<li>
<p>Tilbøjelighed til at bløde eller få blå mærker (på grund af et lavt antal blodplader, de små celler,
der har betydning for blodets evne til at størkne).
Indberetning af bivirkninger
Hvis du oplever bivirkninger, bør du tale med lægen eller apotekspersonalet. Dette gælder også mulige
bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette
bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks
V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om
sikkerheden af dette lægemiddel.</p>
</li>
</ul> </div>"""      
        
* section[=].section[+]
  * title = "5. Opbevaring"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. Opbevaring"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn.
Brug ikke lægemidlet efter den udløbsdato, der står på karton eller blister efter EXP. Udløbsdatoen er
den sidste dag i den nævnte måned.
Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen.
Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du
ikke smide lægemiddelrester i afløbet, toilettet eller skraldespanden.</p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Pakningsstørrelser og yderligere oplysninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Pakningsstørrelser og yderligere oplysninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Sivextro indeholder:</p>
<ul>
<li>
<p>Aktivt stof: tedizolidphosphat. Hver filmovertrukket tablet indeholder 200 mg
tedizolidphosphat.</p>
</li>
<li>
<p>Øvrige indholdsstoffer: mikrokrystallinsk cellulose, mannitol, povidon, crospovidon og
magnesiumstearat i selve tabletkernen. Tablettens filmovertræk indeholder polyvinylalkohol,
titandioxid (E171), macrogol, talcum og gul jernoxid (E172).
43
Udseende og pakningsstørrelser
Sivextro er en oval, gul filmovertrukket tablet præget med "TZD" på den ene side og ’200’ på den
anden side.
Sivextro-tabletterne fås i perforeret enkeltdosisblister med 6 x 1 tabletter.
Indehaver af markedsføringstilladelsen og fremstiller
Merck Sharp &amp; Dohme B.V.
Waarderweg 39
2031 BN Haarlem
Holland
Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale
repræsentant for indehaveren af markedsføringstilladelsen:
België/Belgique/Belgien
MSD Belgium
Tél/Tel: +32(0)27766211
dpoc_belux@merck.com
Lietuva
UAB Merck Sharp &amp; Dohme
Tel.: +370 5 278 02 47
msd_lietuva@merck.com
България 
Мерк Шарп и Доум България ЕООД
Тел.: +359 2 819 3737
info-msdbg@merck.com
Luxembourg/Luxemburg
MSD Belgium
Tél/Tel: +32(0)27766211
dpoc_belux@merck.com
Česká republika
Merck Sharp &amp; Dohme s.r.o.
Tel.: +420 233 010 111
dpoc_czechslovak@merck.com
Magyarország
MSD Pharma Hungary Kft.
Tel.: +36 1 888 5300
hungary_msd@merck.com
Danmark
MSD Danmark ApS
Tlf.: +45 4482 4000
dkmail@merck.com
Malta
Merck Sharp &amp; Dohme Cyprus Limited
Tel: 8007 4433 (+356 99917558)
malta_info@merck.com
Deutschland
MSD Sharp &amp; Dohme GmbH
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)
e-mail@msd.de
Nederland
Merck Sharp &amp; Dohme B.V.
Tel: 0800 9999000 (+31 23 5153153)
medicalinfo.nl@merck.com
Eesti
Merck Sharp &amp; Dohme OÜ
Tel.: +372 6144 200
msdeesti@merck.com
Norge
MSD (Norge) AS
Tlf: +47 32 20 73 00
msdnorge@msd.no
Ελλάδα
MSD Α.Φ.Β.Ε.Ε.
Τηλ: +30 210 98 97 300
dpoc_greece@merck.com
Österreich
Merck Sharp &amp; Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 044
dpoc_austria@merck.com
España
Merck Sharp &amp; Dohme de España, S.A.
Tel: +34 91 321 06 00
msd_info@merck.com
Polska
MSD Polska Sp. z o.o.
Tel.: +48 22 549 51 00
msdpolska@merck.com
44
France
MSD France
Tél: + 33 (0) 1 80 46 40 40
Portugal
Merck Sharp &amp; Dohme, Lda
Tel: +351 21 4465700
inform_pt@merck.com
Hrvatska
Merck Sharp &amp; Dohme d.o.o.
Tel: + 385 1 6611 333
croatia_info@merck.com
România
Merck Sharp &amp; Dohme Romania S.R.L.
Tel: +40 21 529 29 00
msdromania@merck.com
Ireland
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998700
medinfo_ireland@merck.com
Slovenija
Merck Sharp &amp; Dohme, inovativna zdravila d.o.o.
Tel: +386 1 5204 201
msd.slovenia@merck.com
Ísland
Vistor hf.
Sími: + 354 535 7000
Slovenská republika
Merck Sharp &amp; Dohme, s. r. o.
Tel.: +421 2 58282010
dpoc_czechslovak@merck.com
Ιtalia
MSD Italia S.r.l.
Tel: 800 23 99 89 (+39 06 361911)
medicalinformation.it@msd.com
Suomi/Finland
MSD Finland Oy
Puh/Tel: +358 (0)9 804 650
info@msd.fi
Κύπρος
Merck Sharp &amp; Dohme Cyprus Limited
Τηλ.: 800 00 673 (+357 22866700)
cyprus_info@merck.com
Sverige
Merck Sharp &amp; Dohme (Sweden) AB
Tel: +46 77 5700488
medicinskinfo@merck.com
Latvija
SIA Merck Sharp &amp; Dohme Latvija
Tel: +371 67364224
msd_lv@merck.com
United Kingdom (Northern Ireland)
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998700
medinfoNI@msd.com
Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ}.
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs
hjemmeside http://www.ema.europa.eu.
45
Indlægsseddel: Information til patienten
Sivextro 200 mg pulver til koncentrat til infusionsvæske, opløsning
tedizolidphosphat
Læs denne indlægsseddel grundigt, inden du får dette lægemiddel, da den indeholder vigtige
oplysninger.</p>
</li>
<li>Gem indlægssedlen. Du kan få brug for at læse den igen.</li>
<li>Spørg lægen eller sygeplejersken, hvis der er mere, du vil vide.</li>
<li>Kontakt lægen eller sygeplejersken, hvis du får bivirkninger, herunder bivirkninger, som ikke er
nævnt i denne indlægsseddel. Se punkt 4. Se den nyeste indlægsseddel på www.indlaegsseddel.dk.</li>
</ul> </div>"""      



Instance: composition-pt-4c889264e6df1e0383b0ef68358c4009
InstanceOf: CompositionUvEpi
Title: "Composition for sivextro Package Leaflet"
Description:  "Composition for sivextro Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/15/991/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp4c889264e6df1e0383b0ef68358c4009)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - sivextro"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #pt
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. FOLHETO INFORMATIVO"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. FOLHETO INFORMATIVO"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Folheto informativo: Informação para o utilizador"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Folheto informativo: Informação para o utilizador"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "O que contém este folheto"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "O que contém este folheto"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>O que contém este folheto:
1. O que é Sivextro e para que é utilizado
2. O que precisa de saber antes de tomar Sivextro
3. Como tomar Sivextro
4. Efeitos indesejáveis possíveis
5. Como conservar Sivextro 
6. Conteúdo da embalagem e outras informações</p> </div>"""   
          

* section[=].section[+]
  * title =  "1. O que é sivextro e para que é utilizado"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. O que é sivextro e para que é utilizado"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Sivextro é um antibiótico que contém a substância ativa fosfato de tedizolida. Pertence a um grupo de
medicamentos chamados “oxazolidinonas".
É utilizado para tratar adultos e adolescentes com 12 ou mais anos de idade com infeções da pele e dos
tecidos inferiores da pele.
Funciona ao impedir o crescimento de certas bactérias que podem causar infeções graves.</p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. O que precisa de saber antes de tomar sivextro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. O que precisa de saber antes de tomar sivextro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Não tome Sivextro </p>
<ul>
<li>se tem alergia ao fosfato de tedizolida ou a qualquer outro componente deste medicamento
(indicados na secção 6).
Advertências e precauções
O seu médico decidirá se Sivextro é adequado para tratar a sua infeção.
Fale com o seu médico ou farmacêutico antes de tomar Sivextro se alguma das seguintes situações se
aplicar a si:</li>
<li>tem diarreia ou se teve diarreia durante (ou até 2 meses depois) um tratamento com antibióticos
no passado.</li>
<li>tem alergia a outros medicamentos pertencentes ao grupo das “oxazolidinonas" (como por
exemplo linezolida, cicloserina).</li>
<li>tem história de hemorragia ou aparecimento de nódoas negras com facilidade (que pode ser
sinal de um baixo número de plaquetas, pequenas células envolvidas na coagulação do sangue).</li>
<li>tem problemas nos rins.</li>
<li>está a tomar certos medicamentos para tratar a depressão, conhecidos como tricíclicos, ISRSs
(inibidores seletivos da recaptação da serotonina), opioides ou IMAOs (inibidores da
monoaminoxidase). A utilização destes medicamentos com fosfato de tedizolida pode originar
41
síndrome da serotonina, uma situação com potencial risco de vida (com sintomas como
sensação de desorientação, dificuldade de concentração, temperatura elevada, reflexos
aumentados, dificuldade de coordenação dos movimentos musculares). Ver Outros
medicamentos e Sivextro para exemplos.</li>
<li>
<p>está a tomar certos medicamentos para tratar a enxaqueca, conhecidos como “triptanos". Ver
Outros medicamentos e Sivextro para exemplos.
Fale com o seu médico ou farmacêutico, se não tiver a certeza se está a tomar algum destes
medicamentos.
Diarreia
Contacte imediatamente o seu médico se tiver diarreia durante ou depois do tratamento. Não tome
nenhum medicamento para tratar a diarreia sem falar primeiro com o seu médico.
Resistência a antibióticos
Com o tempo, as bactérias podem tornar-se resistentes ao tratamento com antibióticos. Isto acontece
quando os antibióticos não conseguem impedir o desenvolvimento das bactérias e tratar a sua infeção.
O seu médico decidirá se lhe deve ser dado Sivextro para tratar a sua infeção.
Efeitos indesejáveis possíveis
Foram observados certos efeitos indesejáveis com Sivextro ou outro membro da classe das
oxazolidinonas, quando administrados durante um período que exceda o recomendado para Sivextro.
Informe o seu médico de imediato, se sofrer algum dos seguintes durante a toma de Sivextro:</p>
</li>
<li>
<p>tem uma baixa contagem de glóbulos brancos</p>
</li>
<li>
<p>anemia (nível reduzido de glóbulos vermelhos)</p>
</li>
<li>
<p>hemorragia ou aparecimento de nódoas negras com facilidade</p>
</li>
<li>
<p>perda de sensibilidade nas mãos ou pés (como por exemplo, dormência, picadas/formigueiro ou
dores intensas)</p>
</li>
<li>
<p>quaisquer problemas com a sua visão, como visão enevoada, alterações na visão a cores,
dificuldade em ver em pormenor ou se o seu campo de visão ficar limitado.
Crianças
Este medicamento não deve ser utilizado em crianças com idade inferior a 12 anos, uma vez que não
foi suficientemente estudado nesta população.
Outros medicamentos e Sivextro
Informe o seu médico ou farmacêutico se estiver a tomar, tiver tomado recentemente, ou se vier a
tomar outros medicamentos. É especialmente importante que informe o seu médico se estiver também
a tomar:</p>
</li>
<li>
<p>amitriptilina, citalopram, clomipramina, dosulepina, doxepina, fluoxetina, fluvoxamina,
imipramina, isocarboxazida, lofepramina, moclobemida, paroxetina, fenelzina, selegilina,
sertralina, duloxetina e venlafaxina (utilizados para tratar a depressão). Existe o risco de que o
fosfato de tedizolida possa interagir com alguns medicamentos, incluindo os mencionados,
causando efeitos indesejáveis tais como alterações na tensão arterial ou temperatura.</p>
</li>
<li>
<p>sumatriptano, zolmitriptano (utilizados para tratar a enxaqueca)</p>
</li>
<li>
<p>opioides (tal como fentanilo)</p>
</li>
<li>
<p>imatinib, lapatinib (utilizados para tratar o cancro)</p>
</li>
<li>
<p>metotrexato (utilizado para tratar o cancro, artrite reumatoide ou psoríase)</p>
</li>
<li>
<p>sulfassalazina (utilizada para tratar doenças intestinais inflamatórias)</p>
</li>
<li>
<p>topotecano (utilizado para tratar o cancro)</p>
</li>
<li>
<p>estatinas tais como a pitavastatina, rosuvastatina (utilizadas para baixar o colesterol no sangue)
Sivextro pode interferir com os efeitos destes medicamentos. O seu médico explicar-lhe-á melhor.
Gravidez e amamentação
Se está grávida ou a amamentar, se pensa estar grávida ou planeia engravidar, consulte o seu médico
42
ou farmacêutico antes de tomar este medicamento.
Desconhece-se se Sivextro passa para o leite materno nos humanos. Aconselhe-se com o seu médico
antes de amamentar o seu bebé.
Condução de veículos e utilização de máquinas
Não conduza nem utilize máquinas, caso se sinta tonto ou cansado depois de tomar este medicamento.</p>
</li>
</ul> </div>"""   
                    
* section[=].section[+]
  * title =  "3. Como tomar sivextro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. Como tomar sivextro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tome este medicamento exatamente como indicado pelo seu médico ou farmacêutico. Fale com o seu
médico ou farmacêutico se tiver dúvidas.
A dose recomendada é um comprimido de 200 mg, uma vez ao dia, durante 6 dias. Os comprimidos
são engolidos inteiros e podem ser tomados com ou sem alimentos ou bebidas.
Consulte o médico, se não se sentir melhor ou estiver pior passados 6 dias.
Se tomar mais Sivextro do que deveria 
Contacte o mais rápido possível o seu médico, farmacêutico ou a Urgência do hospital mais próximo,
se tiver tomado mais comprimidos do que deveria, e leve a medicação consigo.
Caso se tenha esquecido de tomar Sivextro
Caso se esqueça de tomar o seu medicamento, tome a dose o mais rápido possível até 8 horas antes da
próxima dose agendada. Se faltarem menos de 8 horas para a dose seguinte, espere até à próxima dose
agendada. Não tome uma dose a dobrar para compensar uma dose que se esqueceu de tomar. Em caso
de dúvidas, aconselhe-se com o seu médico.
Deve tomar os 6 comprimidos para completar o ciclo de tratamento, mesmo que se tenha esquecido de
uma dose.
Se parar de tomar Sivextro
Se parar de tomar Sivextro sem o conselho do seu médico, os seus sintomas podem agravar-se. Fale
com o seu médico ou farmacêutico antes de parar de tomar o seu medicamento.
Caso ainda tenha dúvidas sobre a utilização deste medicamento, fale com o seu médico ou
farmacêutico.</p> </div>"""         

        
* section[=].section[+]
  * title = "4. Efeitos indesejáveis possíveis"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Efeitos indesejáveis possíveis"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Como todos os medicamentos, este medicamento pode causar efeitos indesejáveis, embora estes não se
manifestem em todas as pessoas.
Contacte imediatamente o seu médico, se tiver diarreia durante ou depois do tratamento.
Outros efeitos indesejáveis podem incluir:
Efeitos indesejáveis frequentes (podem afetar até 1 em 10 pessoas)</p>
<ul>
<li>
<p>Náuseas</p>
</li>
<li>
<p>Vómitos</p>
</li>
<li>
<p>Dor de cabeça</p>
</li>
<li>
<p>Comichão por todo o corpo</p>
</li>
<li>
<p>Cansaço</p>
</li>
<li>
<p>Tonturas
Efeitos indesejáveis pouco frequentes (podem afetar até 1 em 100 pessoas)</p>
</li>
<li>
<p>Infeções fúngicas da pele, boca e vagina (“sapinhos" orais/vaginais)
43</p>
</li>
<li>
<p>Comichão (incluindo comichão devido a reação alérgica), queda de cabelo, acne, erupção na
pele com vermelhidão e comichão ou urticária, transpiração excessiva </p>
</li>
<li>
<p>Redução ou perda da sensibilidade da pele, sensação de formigueiro/picadas na pele </p>
</li>
<li>
<p>Afrontamentos ou rubores/vermelhidão no rosto, pescoço ou zona superior do peito </p>
</li>
<li>
<p>Abcesso (nódulo inchado cheio de pus) </p>
</li>
<li>
<p>Infeção vaginal, inflamação ou comichão </p>
</li>
<li>
<p>Ansiedade, irritabilidade, arrepios ou tremores</p>
</li>
<li>
<p>Infeção do trato respiratório (seios nasais, garganta e peito)</p>
</li>
<li>
<p>Secura no nariz, congestionamento no peito, tosse </p>
</li>
<li>
<p>Insónia, padrão de sono anormal, dificuldade em dormir, pesadelos (sonhos
desagradáveis/perturbadores)</p>
</li>
<li>
<p>Boca seca, prisão de ventre, indigestão, dor/desconforto na barriga (abdómen), vontade de
vomitar, vómitos em seco, sangue vivo nas fezes</p>
</li>
<li>
<p>Doença de refluxo (azia, dor ou dificuldade em engolir), flatulência/gases </p>
</li>
<li>
<p>Dor na articulação, espasmos musculares, dor nas costas, dor no pescoço, dor/desconforto nos
membros, diminuição na força de mãos</p>
</li>
<li>
<p>Visão enevoada, “moscas" (pequenas formas que se veem a voar no campo de visão)</p>
</li>
<li>
<p>Gânglios linfáticos inchados ou dilatados </p>
</li>
<li>
<p>Reação alérgica </p>
</li>
<li>
<p>Desidratação </p>
</li>
<li>
<p>Fraco controlo da diabetes </p>
</li>
<li>
<p>Paladar alterado </p>
</li>
<li>
<p>Batimento cardíaco lento</p>
</li>
<li>
<p>Febre </p>
</li>
<li>
<p>Inchaço nos tornozelos e/ou pés </p>
</li>
<li>
<p>Urina com cheiro anormal, análises ao sangue alteradas
Frequência desconhecida (a frequência não pode ser calculada a partir dos dados disponíveis)</p>
</li>
<li>
<p>Hemorragia ou aparecimento de nódoas negras com facilidade (devido a um baixo número de
plaquetas, pequenas células envolvidas na coagulação do sangue)
Comunicação de efeitos indesejáveis
Se tiver quaisquer efeitos indesejáveis, fale com o seu médico ou farmacêutico. Isto inclui possíveis
efeitos indesejáveis não indicados neste folheto. Também poderá comunicar efeitos indesejáveis
diretamente através do sistema nacional de notificação mencionado no Apêndice V. Ao comunicar
efeitos indesejáveis, estará a ajudar a fornecer mais informações sobre a segurança deste
medicamento.</p>
</li>
</ul> </div>"""      
        
* section[=].section[+]
  * title = "5. Como conservar sivextro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. Como conservar sivextro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Manter este medicamento fora da vista e do alcance das crianças.
Não utilize este medicamento após o prazo de validade impresso na embalagem exterior, blister ou
rótulo após EXP. O prazo de validade corresponde ao último dia do mês indicado.
O medicamento não necessita de quaisquer precauções especiais de conservação.
Não deite fora quaisquer medicamentos na canalização ou no lixo doméstico. Pergunte ao seu
farmacêutico como deitar fora os medicamentos que já não utiliza. Estas medidas ajudarão a proteger
o ambiente.
44</p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Conteúdo da embalagem e outras informações"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Conteúdo da embalagem e outras informações"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Qual a composição de Sivextro </p>
<ul>
<li>
<p>A substância ativa é fosfato de tedizolida. Cada comprimido revestido por película contém
200 mg de fosfato de tedizolida.</p>
</li>
<li>
<p>Os outros componentes são celulose microcristalina, manitol, povidona, crospovidona e
estearato de magnésio no núcleo do comprimido. O revestimento do comprimido contém álcool
polivinílico, dióxido de titânio (E171), macrogol, talco e óxido de ferro amarelo (E172).
Qual o aspeto de Sivextro e conteúdo da embalagem
Sivextro é um comprimido revestido por película amarelo, oval com “TZD" impresso numa das faces
e “200" na outra.
Está disponível em 6 x 1 comprimidos em blisters unidose perfurados.
Titular da Autorização de Introdução no Mercado e Fabricante
Merck Sharp &amp; Dohme B.V.
Waarderweg 39
2031 BN Haarlem
Países Baixos
Para quaisquer informações sobre este medicamento, queira contactar o representante local do Titular
da Autorização de Introdução no Mercado:
België/Belgique/Belgien
MSD Belgium
Tél/Tel: +32(0)27766211
dpoc_belux@merck.com
Lietuva
UAB Merck Sharp &amp; Dohme
Tel.: +370 5 278 02 47
msd_lietuva@merck.com
България 
Мерк Шарп и Доум България ЕООД
Тел.: +359 2 819 3737
info-msdbg@merck.com
Luxembourg/Luxemburg
MSD Belgium
Tél/Tel: +32(0)27766211
dpoc_belux@merck.com
Česká republika
Merck Sharp &amp; Dohme s.r.o.
Tel.: +420 233 010 111
dpoc_czechslovak@merck.com
Magyarország
MSD Pharma Hungary Kft.
Tel.: +361 888 5300
hungary_msd@merck.com
Danmark
MSD Danmark ApS
Tlf: +45 4482 4000
dkmail@merck.com
Malta
Merck Sharp &amp; Dohme Cyprus Limited
Tel: 8007 4433 (+356 99917558)
malta_info@merck.com
Deutschland
MSD Sharp &amp; Dohme GmbH
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)
e-mail@msd.de
Nederland
Merck Sharp &amp; Dohme B.V.
Tel: 0800 9999000 (+31 23 5153153)
medicalinfo.nl@merck.com
Eesti
Merck Sharp &amp; Dohme OÜ
Tel.: +372 6144 200
msdeesti@merck.com
Norge
MSD (Norge) AS
Tlf: +47 32 20 73 00
msdnorge@msd.no
45
Ελλάδα
MSD Α .Φ.Β.Ε.Ε.
Τηλ: +30 210 98 97 300
dpoc_greece@merck.com
Österreich
Merck Sharp &amp; Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 044
dpoc_austria@merck.com
España
Merck Sharp &amp; Dohme de España, S.A.
Tel: +34 91 321 06 00
msd_info@merck.com
Polska
MSD Polska Sp. z o.o.
Tel.: +48 22 549 51 00
msdpolska@merck.com
France
MSD France
Tél: + 33 (0) 1 80 46 40 40
Portugal
Merck Sharp &amp; Dohme, Lda
Tel: +351 21 4465700
inform_pt@merck.com
Hrvatska
Merck Sharp &amp; Dohme d.o.o. 
Tel: + 385 1 6611 333
croatia_info@merck.com
România
Merck Sharp &amp; Dohme Romania S.R.L.
Tel: +40 21 529 29 00
msdromania@merck.com
Ireland
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998700
medinfo_ireland@merck.com
Slovenija
Merck Sharp &amp; Dohme, inovativna zdravila d.o.o.
Tel: +386 1 5204 201
msd.slovenia@merck.com
Ísland
Vistor hf.
Sími: + 354 535 7000
Slovenská republika
Merck Sharp &amp; Dohme, s. r. o.
Tel.: +421 2 58282010
dpoc_czechslovak@merck.com
Ιtalia
MSD Italia S.r.l.
Tel: 800 23 99 89 (+39 06 361911)
medicalinformation.it@msd.com
Suomi/Finland
MSD Finland Oy
Puh/Tel: +358 (0)9 804 650
info@msd.fi
Κύπρος
Merck Sharp &amp; Dohme Cyprus Limited
Τηλ.: 800 00 673 (+357 22866700)
cyprus_info@merck.com
Sverige
Merck Sharp &amp; Dohme (Sweden) AB
Tel: +46 77 5700488
medicinskinfo@merck.com
Latvija
SIA Merck Sharp &amp; Dohme Latvija
Tel: +371 67364224
msd_lv@merck.com
United Kingdom (Northern Ireland)
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998700
medinfoNI@msd.com
Este folheto foi revisto pela última vez em {MM/AAAA}.
Está disponível informação pormenorizada sobre este medicamento no sítio da internet da Agência</p>
</li>
</ul> </div>"""      





                    
Instance: bundlepackageleaflet-en-4c889264e6df1e0383b0ef68358c4009
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for sivextro Package Leaflet for language en"
Description: "ePI document Bundle for sivextro Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-4c889264e6df1e0383b0ef68358c4009"
* entry[0].resource = composition-en-4c889264e6df1e0383b0ef68358c4009

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp4c889264e6df1e0383b0ef68358c4009"
* entry[=].resource = mp4c889264e6df1e0383b0ef68358c4009
                            
                    
Instance: bundlepackageleaflet-da-4c889264e6df1e0383b0ef68358c4009
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for sivextro Package Leaflet for language da"
Description: "ePI document Bundle for sivextro Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-4c889264e6df1e0383b0ef68358c4009"
* entry[0].resource = composition-da-4c889264e6df1e0383b0ef68358c4009

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp4c889264e6df1e0383b0ef68358c4009"
* entry[=].resource = mp4c889264e6df1e0383b0ef68358c4009
                            
                    
Instance: bundlepackageleaflet-pt-4c889264e6df1e0383b0ef68358c4009
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for sivextro Package Leaflet for language pt"
Description: "ePI document Bundle for sivextro Package Leaflet for language pt"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #pt

// Composition
* entry[0].fullUrl = "Composition/composition-pt-4c889264e6df1e0383b0ef68358c4009"
* entry[0].resource = composition-pt-4c889264e6df1e0383b0ef68358c4009

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp4c889264e6df1e0383b0ef68358c4009"
* entry[=].resource = mp4c889264e6df1e0383b0ef68358c4009
                            
                    



Instance: mp4c889264e6df1e0383b0ef68358c4009
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Sivextro 200 mg film-coated tablets"
Description: "Sivextro 200 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/15/991/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Sivextro 200 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 4c889264e6df1e0383b0ef68358c4009ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "sivextro"

* status = #current
* mode = #working

* title = "List of all ePIs associated with sivextro"

* subject = Reference(mp4c889264e6df1e0383b0ef68358c4009)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#sivextro "sivextro"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-4c889264e6df1e0383b0ef68358c4009) // sivextro en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-4c889264e6df1e0383b0ef68358c4009) // sivextro da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"



* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-pt-4c889264e6df1e0383b0ef68358c4009) // sivextro pt
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "pt"




Instance: List-4c889264e6df1e0383b0ef68358c4009
InstanceOf: List
Description: "ePI document List for sivextro Package Leaflets"

* insert 4c889264e6df1e0383b0ef68358c4009ListRuleset
    